Hangzhou Qihan Biotech Co., Ltd. Listed by Global Ransomware Group

Your information appears on a ransomware group's leak site. Hangzhou Qihan Biotech has been listed by a ransomware-extortion crew claiming to have taken data from the company on 12 August 2026. The group posted the listing on 28 August 2026, sixteen days later. The company has not publicly confirmed the claim as of this writing.

This means the only thing you can treat as established today is that your records are included in an unverified claim. No independent party has validated the incident, the volume of data, or whether any files actually left Qihan Biotech’s systems. That uncertainty is the starting point for every decision you make now.

What a Leak-Site Listing Actually Establishes

Ransomware crews maintain public leak sites to pressure victims into paying. The listing itself is marketing material produced by the attacker. It may contain real data, recycled material from an earlier incident, exaggerated claims, or in some cases entirely fabricated entries intended to damage reputation or extract payment without any successful intrusion.

History shows a meaningful percentage of these postings are later walked back, proven overstated, or quietly removed when no payment arrives. Without confirmation from the company, a regulator, or a forensic report, the listing remains exactly what it is: an accusation, not evidence. Real confirmation would require the organisation to acknowledge the incident, regulators to issue notices, or third-party analysis matching samples to known records. None of those exist here.

Until that changes, treat this as a possible exposure rather than a confirmed one. This protects you from over-reacting to noise while still prompting reasonable precautions.

The Biotech Sector Pattern

Biotech and life-sciences organisations have become an expanding target class for ransomware operators. These companies hold intellectual property around gene editing, cell therapies, and clinical trial data that can be extremely valuable on secondary markets. Patient-related records, when present, add another layer of leverage because of regulatory sensitivity.

The pattern does not prove this specific incident occurred, but it explains why a crew might choose to list a company like Hangzhou Qihan Biotech, which works on immune-privileged cells and xenogeneic organs for cancer and organ-failure treatments. If files were taken, firms in this sector typically hold research data, partner contracts, employee records, and in some cases information related to clinical participants or donors. The absence of any enumerated categories in the public filing means you cannot know which, if any, of those applied to you.

If You Receive a Notification Letter

The organisation is required to notify affected individuals directly, usually by post to the address they hold. If you receive such a letter it will tell you exactly which categories of information were involved in your specific case. Absence of a letter usually indicates you were not in the affected group. However, if you have moved since the incident date of 12 August 2026, the letter may have gone to an old address. In that situation contact Qihan Biotech directly to confirm your status.

The filing does not state how many people were affected, nor does it name any specific categories of information. Those details remain unknown to the public.

Immediate actions you should take today, ordered by priority:

• Do this before the end of the day.
• Enable multi-factor authentication on every account that supports it, especially email, banking, and any healthcare portals. App-based authenticators are strongest.
• Monitor your accounts and credit reports for unusual activity over the next several months. Set alerts where possible.
• Be wary of unsolicited contact claiming to be from Qihan Biotech or offering help with this incident. Scammers frequently exploit leak-site listings.
• Consider ongoing monitoring that tracks your information across 13.1 billion breach records and more than 100 platforms. GalaxyWarden provides continuous surveillance, identity-chain mapping, and specialist remediation support.